Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e15267 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e15267-e15267

Author(s):

Hiroaki Yanagimoto ◽

Takuji Okusaka ◽

Hiroshi Ishii ◽

Junji Furuse ◽

Shinichi Ohkawa ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Oral Therapy ◽

Phase Ii Trial ◽

Advanced Pancreatic Cancer ◽

Line Treatment ◽

Standard Regimen ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4107 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4107-4107

Author(s):

Masayuki Sho ◽

Atsushi Shimizu ◽

Hiroaki Yanagimoto ◽

Shoji Nakamori ◽

Takuji Okusaka ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Oral Therapy ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

Standard Regimen ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group

European Journal of Cancer ◽

10.1016/s0959-8049(03)00629-4 ◽

2003 ◽

Vol 39 (16) ◽

pp. 2334-2340 ◽

Author(s):

E Briasoulis ◽

N Pavlidis ◽

C Terret ◽

J Bauer ◽

W Fiedler ◽

...

Keyword(s):

Pancreatic Cancer ◽

Drug Development ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Pancreatic Cancer ◽

Line Treatment ◽

New Drug Development ◽

Development Group ◽

First Line Treatment

Download Full-text

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4000 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4000-4000 ◽

Author(s):

Laetitia Dahan ◽

Jean Marc Phelip ◽

Karine Le Malicot ◽

Nicolas Williet ◽

Jérôme Desrame ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Maintenance Treatment ◽

Phase Ii Trial ◽

Sequential Treatment ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps223 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS223-TPS223 ◽

Author(s):

P. A. Philip ◽

B. H. Goldman ◽

R. K. Ramanathan ◽

H. Lenz ◽

A. M. Lowy ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)

Annals of Oncology ◽

10.1093/annonc/mdy281.154 ◽

2018 ◽

Vol 29 ◽

pp. viii202

Author(s):

A. De Stefano ◽

G. Nasti ◽

A. Febbraro ◽

G. Rosati ◽

F. Giuliani ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text